

## Xiaoban Xin

### Senior Associate

#### Washington DC

T +1 202 457 7567

[xiaoban.xin@squirepb.com](mailto:xiaoban.xin@squirepb.com)

#### Languages spoken

English | Mandarin Chinese



### About Xiaoban

Xiaoban Xin focuses his practice on patent prosecution and portfolio development, strategy and due diligence. He has extensive experience preparing, prosecuting and evaluating patents in a broad range of technical areas in the life sciences sector, including biologics (e.g., antibodies, peptides, RNAs, etc.), gene editing, cell therapy, drug delivery vehicles, next generation sequencing and small molecules. He also has worked with medical devices, chemical engineering and materials, energy and clean tech, mechanical engineering and health IT.

Xiaoban reviews each client's business and technology with a critical eye so he can bring a detailed understanding of the science at issue. He believes in partnering with his clients to formulate the patent strategy that best suits their business objectives. He regularly works with in-house counsel, senior management and technology transfer office managers, and often serves as the link between inventor and marketplace.

Xiaoban provides due diligence for commercial transactions, including evaluation of the strength, scope and potential of patents of prospective partners and competitors, as well as general diligence in support of investment or mergers and acquisitions projects.

Xiaoban has been extensively involved in prior art search and analysis, invalidity, non-infringement position development, and drafting briefs in support of patent litigation, including USPTO proceedings and court litigation.

Prior to his legal career, Xiaoban gained extensive experience in biomedical research. Xiaoban holds a Ph.D. in cellular and molecular biology and completed a technology transfer fellowship with The National Institute of Allergy and Infectious Diseases at the National Institutes of Health, and a post-doctoral research fellowship with The Johns Hopkins University School of Medicine.

During his studies at George Washington University Law School, Xiaoban served as editor of the *American Intellectual Property Law Association Quarterly Journal*.

Xiaoban is fluent in Mandarin Chinese.

### Credentials

### Education

- George Washington University Law School, J.D., 2016
- University of Texas Health Science Center, Ph.D., 2011
- Nanjing University, B.S., 2004

## Admissions

- U.S. Patent and Trademark Office
- District of Columbia, 2017
- Maryland, 2016

## Recognitions

- JD Supra: Top Authors in Life Sciences, 2021

## Expertise

### Services

- Intellectual Property & Technology

### Industries

- Life Sciences

## Publications & Speaking Engagements

- Speaker, "Strategies of patenting antibody drug conjugates in the U.S.", IP Link Workshop, January, 2026.
- Speaker, "High-value Patent Strategies in Life Sciences From a Global Perspective", Merits & Tree IP Conference, March 2024.
- Speaker, "Patent Strategies for Growth Stage Companies," H7 BioCapital Healthcare Workshop, November 2023.
- Speaker, "What Startup Founders Should Know about Patents," MIT Chinese Entrepreneur Organization, 1 October 2023.
- Speaker, "Patent Strategies for Chinese Antibody Companies Exploring the U.S. Market," 2022 Antibody Drug Industry Summit, China, 3 August 2022.
- Speaker, "Patent Strategy for Biotech Companies," MedLab InnoTalk, 8 March 2022.

## About our firm

One of the world's strongest integrated law firms, providing insight at the point where law, business and government meet. We deliver commercially focused business solutions by combining our legal, lobbying and political capabilities and invaluable connections on the ground to a diverse mix of clients, from long-established leading corporations to emerging businesses, startup visionaries and sovereign nations. More than 1,500 lawyers in over 40 offices across four continents provide unrivaled access to expertise.